Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

The Contribution of MMP-8 Promoter Polymorphisms in Lung Cancer

TE-CHUN SHEN, TE-CHUN HSIA, CHE-YI CHAO, WEI-CHENG CHEN, CHIH-YU CHEN, WEI-CHUN CHEN, YI-TING LIN, CHIEH-LUN HSIAO, WEN-SHIN CHANG, CHIA-WEN TSAI and DA-TIAN BAU
Anticancer Research July 2017, 37 (7) 3563-3567;
TE-CHUN SHEN
1Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan, R.O.C.
2Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, R.O.C.
3Terry Fox Cancer Research Laboratory, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TE-CHUN HSIA
2Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, R.O.C.
3Terry Fox Cancer Research Laboratory, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHE-YI CHAO
4Department of Health and Nutrition Biotechnology, Asia University, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
WEI-CHENG CHEN
2Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHIH-YU CHEN
2Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
WEI-CHUN CHEN
2Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YI-TING LIN
3Terry Fox Cancer Research Laboratory, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHIEH-LUN HSIAO
3Terry Fox Cancer Research Laboratory, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
WEN-SHIN CHANG
3Terry Fox Cancer Research Laboratory, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHIA-WEN TSAI
3Terry Fox Cancer Research Laboratory, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: datian@mail.cmuh.org.tw artbau2@gmail.com
DA-TIAN BAU
1Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan, R.O.C.
3Terry Fox Cancer Research Laboratory, China Medical University Hospital, Taichung, Taiwan, R.O.C.
5Department of Bioinformatics and Medical Engineering, Asia University, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: datian@mail.cmuh.org.tw artbau2@gmail.com
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Accumulated evidence has supported the hypothesis that the functional polymorphisms of matrix metalloproteinases (MMP) were associated with the risk of various types of cancer. However, few reports have studied the contribution of MMP-8 genotypes to either diagnostic or prognostic potential in lung cancer. In this study, we focused on the contribution of a polymorphism in the promoter region of MMP-8 (C-799T) and two non-synonymous polymorphisms (Val436Ala and Lys460Thr) to lung cancer risk. Patients and Methods: Genomic DNA was isolated from peripheral blood of 358 patients with lung cancer and 716 non-cancer healthy individuals. MMP-8 C-799T (rs11225395), Val436Ala (rs34009635) and Lys460Thr (rs35866072) polymorphic genotypes of each subject were determined using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Results: The results showed that the three polymorphisms were not significantly associated with increased risk of lung cancer in the overall investigated population. Furthermore, when the analyses were stratified according to age, sex, status of smoking and drinking, pack-years of smoking and family history of lung cancer, there was also no significant association between these genotypes and increased lung cancer risk. Conclusion: The polymorphisms MMP-8 C-799T, Val436Ala and Lys460Thr may not play a major role in mediating personal susceptibility to lung cancer in Taiwan.

  • Genotype
  • lung cancer
  • MMP-8
  • nonsynonymous
  • polymorphism
  • promoter

Worldwide, lung cancer has been the leading cause of cancer mortality for many years (1, 2). Even though personalized antitumor therapies, mainly based on epidermal growth factor receptor (EGFR) genotype, are being developed, the prognosis of patients with lung cancer remains unsatisfying, with a 5-year survival rate of less than 20% (1). Thus, other useful genomic markers may strengthen the current predictive systems for revealing the personalized lung etiology for each patient about their genetic and environmental factors and personalized therapeutic strategies.

Matrix metalloproteinases (MMPs), a family of zinc and calcium-dependent proteolytic enzymes are in charge of regulating the aggravation of extracellular matrix and basement membranes (3-5). MMPs play an important role in many physiological and pathological events during carcinogenesis, such as cell proliferation, differentiation, apoptosis, invasion, migration, metastasis, angiogenesis and immune surveillance (6). Previous literature indicated that functional polymorphisms of MMPs play a role in determining inter-individual differences of susceptibility to several types of cancer (7-14).

In literature, the C-799T genotypes of MMP-8 were reported to be associated with breast cancer (15) and the electrophoretic mobility shift assays revealed differences in nuclear protein binding to oligonucleotides representing the C-799T genotypes (16). The promoter constructs containing the CT and TT genotypes at the C-799T had a 3-fold greater activity in chorion-like trophoblast cells compared to the constructs containing the C alleles (16). However, the role of MMP-8 genotypes was seldom examined in lung cancer (17). The current study aimed at investigating the contribution of MMP-8 C-799T, Val436Ala and Lys460Thr polymorphisms to the susceptibility of lung cancer in Taiwan.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Distribution of selected demographics of the 358 patients with lung cancer and the 716 matched controls.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Summary of primer sequences, specific restriction enzymes, PCR and digestion product sizes.

Materials and Methods

Patients and controls. Three hundred and fifty-eight patients were histologically confirmed with lung cancer and recruited by the surgery team at the Outpatient Clinics of General Surgery at the China Medical University Hospital as previously described (18-20). The exclusion criteria of the patient group were any patient with history of any other malignancy and pulmonary diseases, such as chronic obstructive pulmonary disease (COPD), pneumothorax and asthma. All participants voluntarily completed a self-administered questionnaire and provided a 3- to 5-ml sample of peripheral blood. At the same time, seven hundred and sixteen non-lung cancer healthy volunteers as controls were selected by matching for age, gender and smoking behavior after initial random sampling from the databank of Health Examination Cohort of China Medical University Hospital with more than 10,000 subjects. The exclusion criteria of the control group included previous malignancy, metastasized cancer from other or unknown origin and any genetic or familial diseases. The study was approved by the Institutional Review Board of the China Medical University Hospital with the document coded DMR100-IRB-284 and written informed consent was obtained from all participants. Selected recorded characteristics of the subjects in case and control groups are summarized and compared in Table I.

Methodology of MMP-8 genotyping. Genomic DNA from peripheral blood of each participant was extracted, aliquoted and stored as previously described (21-23). Briefly, the primers for MMP-8 C-799T, Val436Ala and Lys460Thr polymorphisms were custom designed by our team (shown in Table II) and the genotyping polymerase chain reaction (PCR) cycling conditions via My Cycler (Biorad, Hercules, CA, USA) for MMP-8 were: one cycle at 94°C for 5 min; 35 cycles of 94°C for 30 s, 57°C for 30 s and 72°C for 30 s and a final extension at 72°C for 10 min.

Statistical analysis. Goodness-of-fit test was used in order to ensure that the controls recruited were representative of the general population and to exclude the possibility of genotyping error. Pearson's Chi-square test without Yates' correction or Fisher's exact test was used to compare the distribution of the MMP-8 genotypes between case and control groups. The associations between the MMP-8 polymorphisms and lung cancer risk were estimated by computing odds ratios (ORs) as well as their 95% confidence intervals (CIs) from unconditional logistic regression analysis with the adjustment for possible confounding factors.

Results

Basic characteristics compared between the lung cancer patient and control groups. The frequency distributions of the characteristics for lung cancer among the case subjects and control are summarized and compared in Table I. No difference was found between the two groups as for age, gender and smoking status (all p>0.05). Additionally, there was no difference between the two groups as for alcohol drinking status (p>0.05) (Table I).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Distributions of matrix metalloproteinase-8 (MMP-8) genotypic frequencies among the lung cancer cases and the control group.

Association analysis of MMP-8 genotypes at C-799T, Val436Ala and Lys460Thr with lung cancer risk. The distributions of genetic frequencies for the MMP-8 polymorphisms in the lung cancer patients and controls are presented and compared in Table III. First, there were no CT or CC genotypes at MMP-8 Val436Ala among either the cases or the controls. That is to say, all the subjects were of TT genotype at MMP-8 Val436Ala (Table III, lowest panel). Second, the ORs with adjusting those possible confounding factors (age, gender and smoking status) for the people carrying variant CT and TT genotypes at MMP-8 promoter C-799T were 0.87 (95% CI=0.68-1.23, p=0.3999) and 0.79 (95% CI=0.51-1.24, p=0.3198) respectively, compared to those carrying the CC wild-type genotype (Table III, upper panel). The p-value for trend was not significant (p=0.5130) (Table III). In the dominant model (CT plus TT vs. CC), the association between MMP-8 promoter C-799T polymorphism and the risk for lung cancer was still not statistically significant (adjusted OR=0.83, 95% CI=0.59-1.17, p=0.2807) (Table III, upper panel). Third, a very small percentage of Taiwanese people were of heterozygous variant AC genotype at MMP-8 Lys460Thr (0.8% and 0.6% in lung cancer patient and control groups, respectively) and there was no association between MMP-8 Lys460Thr AC genotypes and the risk for lung cancer (adjusted OR=1.53, 95% CI=0.38-6.81, p=0.5931) (Table III, medium panel).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table IV.

Allelic frequencies for matrix metalloproteinase-8 (MMP-8) polymorphisms in the lung cancer cases and control groups.

Association of MMP-8 allelic types at C-799T, Val436Ala and Lys460Thr and lung cancer risk. The adjusted OR for the subjects carrying the T allele at MMP-8 promoter C-799T was 0.84 (95% CI=0.65-1.38, p=0.2225), compared to those carrying the C wild-type allele (Table IV). Supporting the findings in Table III, there is no differential distribution of allelic frequencies between lung cancer patient and control groups as for the MMP-8 promoter C-799T or Lys460Thr (Table IV). As for the allelic frequencies at MMP-8 Val436Ala and Lys460Thr polymorphic sites, there was no association between their genotypes and increased lung cancer risk (Table IV).

Discussion

In the literature, the genotypes of SNPs at promoter region of many MMP genes were found to be associated with the risk of several types of cancer (7-14). However, only Gonzalez-Arriaga's team investigated one polymorphism in MMP-8 as risk factor for lung cancer (17). In that work, the samples were composed of 501 lung cancer cases and 501 healthy controls, all of whom were Caucasian. The authors examined only the C+17G genotypes of MMP-8 gene and found that the G variant allele was associated with a decreased risk of developing lung cancer, while there was no contribution of the particular polymorphism to the overall survival rates for the lung cancer patients (17). In the present study, we examined the genotypes of specific MMP-8 polymorphisms among a Taiwanese population and assessed whether there was an association between the genotypes of the promoter region of MMP-8 (C-799T) and two nonsynonymous polymorphisms (Val436Ala and Lys460Thr) with lung cancer risk. The results showed that no significant association was observed and our findings suggest that these three MMP-8 polymorphisms may not play a critical role in mediating susceptibility to lung cancer (Tables III and IV).

We focused on the genotypes of promoter region of MMP-8 (C-799T) based on certain observations; some studies in mice models showed that mutant mice deficient in MMP-8 were more susceptible to develop skin cancer (24, 25). This evidence from knockout mice models strongly suggested that MMP-8 may play a protective role against carcinogenesis (24, 25). Furthermore, there exist certain positive epidemiological findings, which reported that genotypes of promoter regions of other MMPs such as MMP-1 and MMP-9, may serve as promising markers for the prediction of lung cancer susceptibility and prognosis (26-28). From the viewpoint of protein expression and function, elevated MMP-8 might increase cell adhesion by rearrangement of cytoskeleton actin, thus decreasing cell invasion (29). However, there is lack of epidemiological studies investigating the role of polymorphisms in the promoter region of MMP-8 to the susceptibility of cancers.

In the current study, the results summarized that the genotypes of MMP-8 C-799T (Tables III and IV) in addition to two nonsynonymous polymorphisms (Val436Ala and Lys460Thr) (Tables III and IV) were not associated with lung cancer risk in the Taiwanese population. Furthermore, when the analyses were stratified by age, sex, status of smoking and drinking, pack-years of smoking, and family history of lung cancer, no significant association between these genotypes and lung cancer risk was observed (data not shown). In 2016, we also revealed that the genotypes of tissue inhibitors of metalloproteinase 1 (TIMP-1), which is reported to be in charge of regulation the expression level of extracellular MMP-1, was also associated with lung cancer susceptibility (21). The biological function of MMPs and the TIMPs apparently is more complex than being proved only to involve in controlling the proliferation and metastasis of cancer cells (30, 31), so further studies would be required to elucidate the molecular mechanisms implicated in these complex processes. The phenotypic data including the expression levels of MMP-8 at mRNA or protein are not currently available for further analysis. The complete correlation of patient status, genotype and phenotype would be very helpful to reveal the role of MMP-8 in lung carcinogenesis.

In conclusion, this is the first study to investigate the role of MMP-8 promoter together with nonsynonymous polymorphic genotypes in lung carcinogenesis. Our results suggest that the genotypes of promoter region C-799T and non-synonymous Val436Ala and Lys460Thr at MMP-8, do not significantly confer susceptibility to lung cancer in a Taiwanese population. Further studies elucidating the contribution of the genotypes of other members of MMP family to lung cancer risk are needed.

Acknowledgements

The Authors declare no conflicts of interest. The Authors are grateful to Hsin-Ting Li and Shiou-Ting Yen for their excellent technical assistance. All the participants in this study are appreciated. This study was supported mainly by China Medical University to Dr. Hsia (DMR-CELL-17001), by Asia University to Dr. Bau, Dr. Hsia, and Dr. Chao (CMU105-ASIA-17) and partially by research grant from Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW106-TDU-B-212-113004). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Footnotes

  • ↵* These Authors contributed equally to this study.

  • Received April 24, 2017.
  • Revision received May 13, 2017.
  • Accepted May 26, 2017.
  • Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. Siegel RL,
    2. Miller KD,
    3. Jemal A
    : Cancer statistics, 2015. CA Cancer J Clin 65: 5-29, 2015.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Torre LA,
    2. Bray F,
    3. Siegel RL,
    4. Ferlay J,
    5. Lortet-Tieulent J,
    6. Jemal A
    : Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108, 2015.
    OpenUrlCrossRefPubMed
  3. ↵
    1. de Souza AP,
    2. Trevilatto PC,
    3. Scarel-Caminaga RM,
    4. Brito RB,
    5. Line SR
    : MMP-1 promoter polymorphism: association with chronic periodontitis severity in a Brazilian population. J Clin Periodontol 30: 154-158, 2003.
    OpenUrlCrossRefPubMed
    1. Werb Z
    : ECM and cell surface proteolysis: regulating cellular ecology. Cell 91: 439-442, 1997.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Sternlicht MD,
    2. Werb Z
    : How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17: 463-516, 2001.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Egeblad M,
    2. Werb Z
    : New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Tsai CW,
    2. Chang WS,
    3. Gong CL,
    4. Shih LC,
    5. Chen LY,
    6. Lin EY,
    7. Li HT,
    8. Yen ST,
    9. Wu CN,
    10. Bau DT
    : Contribution of matrix metallopeptidase-1 genotypes, smoking, alcohol drinking and areca chewing to nasopharyngeal carcinoma susceptibility. Anticancer Res 36: 3335-3340, 2016.
    OpenUrlAbstract/FREE Full Text
    1. Sun KT,
    2. Tsai CW,
    3. Chang WS,
    4. Shih LC,
    5. Chen LY,
    6. Tsai MH,
    7. Ji HX,
    8. Hsiao CL,
    9. Liu YC,
    10. Li CY,
    11. Bau DT
    : The contribution of matrix metalloproteinase-1 genotype to oral cancer susceptibility in Taiwan. In Vivo 30: 439-444, 2016.
    OpenUrlAbstract/FREE Full Text
    1. Ye S
    : Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol 19: 623-629, 2000.
    OpenUrlCrossRefPubMed
    1. Price SJ,
    2. Greaves DR,
    3. Watkins H
    : Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 276: 7549-7558, 2001.
    OpenUrlAbstract/FREE Full Text
    1. Yu C,
    2. Zhou Y,
    3. Miao X,
    4. Xiong P,
    5. Tan W,
    6. Lin D
    : Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res 64: 7622-7628, 2004.
    OpenUrlAbstract/FREE Full Text
    1. Elander N,
    2. Soderkvist P,
    3. Fransen K
    : Matrix metalloproteinase (MMP) -1, -2, -3 and -9 promoter polymorphisms in colorectal cancer. Anticancer Res 26: 791-795, 2006.
    OpenUrlAbstract/FREE Full Text
    1. Li Y,
    2. Jin X,
    3. Kang S,
    4. Wang Y,
    5. Du H,
    6. Zhang J,
    7. Guo W,
    8. Wang N,
    9. Fang S
    : Polymorphisms in the promoter regions of the matrix metalloproteinases-1, -3, -7, and -9 and the risk of epithelial ovarian cancer in China. Gynecol Oncol 101: 92-96, 2006.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Hu Z,
    2. Huo X,
    3. Lu D,
    4. Qian J,
    5. Zhou J,
    6. Chen Y,
    7. Xu L,
    8. Ma H,
    9. Zhu J,
    10. Wei Q,
    11. Shen H
    : Functional polymorphisms of matrix metalloproteinase-9 are associated with risk of occurrence and metastasis of lung cancer. Clin Cancer Res 11: 5433-5439, 2005.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Decock J,
    2. Long JR,
    3. Laxton RC,
    4. Shu XO,
    5. Hodgkinson C,
    6. Hendrickx W,
    7. Pearce EG,
    8. Gao YT,
    9. Pereira AC,
    10. Paridaens R,
    11. Zheng W,
    12. Ye S
    : Association of matrix metalloproteinase-8 gene variation with breast cancer prognosis. Cancer Res 67: 10214-10221, 2007.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Wang H,
    2. Parry S,
    3. Macones G,
    4. Sammel MD,
    5. Ferrand PE,
    6. Kuivaniemi H,
    7. Tromp G,
    8. Halder I,
    9. Shriver MD,
    10. Romero R,
    11. Strauss JF 3rd.
    : Functionally significant SNP MMP8 promoter haplotypes and preterm premature rupture of membranes (PPROM). Hum Mol Genet 13: 2659-2669, 2004.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Gonzalez-Arriaga P,
    2. Lopez-Cima MF,
    3. Fernandez-Somoano A,
    4. Pascual T,
    5. Marron MG,
    6. Puente XS,
    7. Tardon A
    : Polymorphism +17 C/G in matrix metalloprotease MMP8 decreases lung cancer risk. BMC Cancer 8: 378, 2008.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Liu CS,
    2. Tsai CW,
    3. Hsia TC,
    4. Wang RF,
    5. Liu CJ,
    6. Hang LW,
    7. Chiang SY,
    8. Wang CH,
    9. Tsai RY,
    10. Lin CC,
    11. Bau DT
    : Interaction of methylenetetrahydrofolate reductase genotype and smoking habit in Taiwanese lung cancer patients. Cancer Genomics Proteomics 6: 325-329, 2009.
    OpenUrlAbstract/FREE Full Text
    1. Hsia TC,
    2. Tsai CW,
    3. Liang SJ,
    4. Chang WS,
    5. Lin LY,
    6. Chen WC,
    7. Tu CY,
    8. Tsai CH,
    9. Bau DT
    : Effects of ataxia telangiectasia mutated (ATM) genotypes and smoking habits on lung cancer risk in Taiwan. Anticancer Res 33: 4067-4071, 2013.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Chen HJ,
    2. Chang WS,
    3. Hsia TC,
    4. Miao CE,
    5. Chen WC,
    6. Liang SJ,
    7. Chen AC,
    8. Chang JG,
    9. Tsai CW,
    10. Hsu CM,
    11. Tsai CH,
    12. Bau DT
    : Contribution of genotype of DNA double-strand break repair gene XRCC3, gender and smoking behavior to lung cancer risk in Taiwan. Anticancer Res 35: 3893-3899, 2015.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Lai CY,
    2. Chang WS,
    3. Hsieh YH,
    4. Hsu CM,
    5. Tsai CW,
    6. Chen AC,
    7. Wang CH,
    8. Bau DT
    : Association of tissue inhibitor of metalloproteinase-1 genotypes with lung cancer risk in Taiwan. Anticancer Res 36: 155-160, 2016.
    OpenUrlAbstract/FREE Full Text
    1. Pei JS,
    2. Hsu PC,
    3. Chou AK,
    4. Tsai CW,
    5. Chang WS,
    6. Hsiao CL,
    7. Hsu YN,
    8. Cheng SP,
    9. Bau DT
    : Matrix metalloproteinase-1 genotype contributes to the risk of non-solid tumor in childhood leukemia. Anticancer Res 36: 5127-5132, 2016.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Chang WS,
    2. Liao CH,
    3. Tsai CW,
    4. Hu PS,
    5. Wu HC,
    6. Hsu SW,
    7. Hsiao CL,
    8. Hsu CH,
    9. Hung YW,
    10. Bau DT
    : Association of enhancer of zeste 2 (EZH2) genotypes with bladder cancer risk in Taiwan. Anticancer Res 36: 4509-4514, 2016.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Balbin M,
    2. Fueyo A,
    3. Tester AM,
    4. Pendas AM,
    5. Pitiot AS,
    6. Astudillo A,
    7. Overall CM,
    8. Shapiro SD,
    9. Lopez-Otin C
    : Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet 35: 252-257, 2003.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Montel V,
    2. Kleeman J,
    3. Agarwal D,
    4. Spinella D,
    5. Kawai K,
    6. Tarin D
    : Altered metastatic behavior of human breast cancer cells after experimental manipulation of matrix metallo-proteinase 8 gene expression. Cancer Res 64: 1687-1694, 2004.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Liu B,
    2. Yi M,
    3. Tang Y,
    4. Liu Q,
    5. Qiu H,
    6. Zou Y,
    7. Peng P,
    8. Zhang L,
    9. Hu C,
    10. Yuan X
    : MMP-1 promoter polymorphism is associated with risk of radiation-induced lung injury in lung cancer patients treated with radiotherapy. Oncotarget 7: 70175-70184, 2016.
    OpenUrl
    1. Bayramoglu A,
    2. Gunes HV,
    3. Metintas M,
    4. Degirmenci I,
    5. Mutlu F,
    6. Alatas F
    : The association of MMP-9 enzyme activity, MMP-9 C1562T polymorphism, and MMP-2 and -9 and TIMP-1, -2, -3, and -4 gene expression in lung cancer. Genet Test Mol Biomarkers 13: 671-678, 2009.
    OpenUrlPubMed
  18. ↵
    1. Liu L,
    2. Wu J,
    3. Wu C,
    4. Wang Y,
    5. Zhong R,
    6. Zhang X,
    7. Tan W,
    8. Nie S,
    9. Miao X,
    10. Lin D
    : A functional polymorphism (-1607 1G-->2G) in the matrix metalloproteinase-1 promoter is associated with development and progression of lung cancer. Cancer 117: 5172-5181, 2011.
    OpenUrl
  19. ↵
    1. Gutierrez-Fernandez A,
    2. Fueyo A,
    3. Folgueras AR,
    4. Garabaya C,
    5. Pennington CJ,
    6. Pilgrim S,
    7. Edwards DR,
    8. Holliday DL,
    9. Jones JL,
    10. Span PN,
    11. Sweep FC,
    12. Puente XS,
    13. Lopez-Otin C
    : Matrix metalloproteinase-8 functions as a metastasis suppressor through modulation of tumor cell adhesion and invasion. Cancer Res 68: 2755-2763, 2008.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Lopez-Otin C,
    2. Matrisian LM
    : Emerging roles of proteases in tumour suppression. Nat Rev Cancer 7: 800-808, 2007.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Hsia TC,
    2. Yu CC,
    3. Hsiao YT,
    4. Wu SH,
    5. Bau DT,
    6. Lu HF,
    7. Huang YP,
    8. Lin JG,
    9. Chang SJ,
    10. Chung JG
    : Cantharidin impairs cell migration and invasion of human lung cancer NCI-H460 cells via UPA and MAPK signaling pathways. Anticancer Res 36: 5989-5997, 2016.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Anticancer Research: 37 (7)
Anticancer Research
Vol. 37, Issue 7
July 2017
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Contribution of MMP-8 Promoter Polymorphisms in Lung Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
4 + 10 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
The Contribution of MMP-8 Promoter Polymorphisms in Lung Cancer
TE-CHUN SHEN, TE-CHUN HSIA, CHE-YI CHAO, WEI-CHENG CHEN, CHIH-YU CHEN, WEI-CHUN CHEN, YI-TING LIN, CHIEH-LUN HSIAO, WEN-SHIN CHANG, CHIA-WEN TSAI, DA-TIAN BAU
Anticancer Research Jul 2017, 37 (7) 3563-3567;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
The Contribution of MMP-8 Promoter Polymorphisms in Lung Cancer
TE-CHUN SHEN, TE-CHUN HSIA, CHE-YI CHAO, WEI-CHENG CHEN, CHIH-YU CHEN, WEI-CHUN CHEN, YI-TING LIN, CHIEH-LUN HSIAO, WEN-SHIN CHANG, CHIA-WEN TSAI, DA-TIAN BAU
Anticancer Research Jul 2017, 37 (7) 3563-3567;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • The Association of MMP-11 Promoter Polymorphisms With Susceptibility to Lung Cancer in Taiwan
  • The Contribution of MMP-7 Promoter Polymorphisms to Taiwan Lung Cancer Susceptibility
  • Association of Matrix Metalloproteinase-7 Genotypes with the Risk of Bladder Cancer
  • Association of Matrix Metalloproteinase-8 Genotypes with the Risk of Bladder Cancer
  • The Association of Matrix Metalloproteinase-1 Promoter Polymorphisms with Prostate Cancer in Taiwanese Patients
  • The Association of Matrix Metalloproteinase-1 Promoter Polymorphisms with Breast Cancer
  • Association of Matrix Metalloproteinase-7 Genotypes to the Risk of Oral Cancer in Taiwan
  • The Association of Matrix Metalloproteinase-8 Promoter Genotypes in Breast Cancer
  • The Contribution of Matrix Metalloproteinase-1 Promoter Genotypes in Taiwan Lung Cancer Risk
  • The Association of MMP-8 Genotypes with Pterygium
  • Contribution of Matrix Metalloproteinase-7 Genotypes to the Risk of Non-solid Tumor, Childhood Leukemia
  • The Contribution of MMP-8 Promoter Genotypes to Childhood Leukemia
  • The Contribution of Matrix Metalloproteinase-7 Promoter Genotypes in Breast Cancer in Taiwan
  • Google Scholar

More in this TOC Section

  • The Prognostic Significance of p16 and its Role as a Surrogate Marker for Human Papilloma Virus in Oral Squamous Cell Carcinoma: An Analysis of 281 Cases
  • Diagnostic Value of Circulating Cell-free DNA in Patients With Papillary Thyroid Cancer
  • Changes in Lysophospholipid Components in Ulcerative Colitis and Colitis-associated Cancer
Show more Experimental Studies

Similar Articles

Keywords

  • genotype
  • Lung cancer
  • MMP-8
  • nonsynonymous
  • polymorphism
  • promoter
Anticancer Research

© 2022 Anticancer Research

Powered by HighWire